Aurora Cannabis and Vectura Fertin Pharma, Inc. announce launch of novel Luo CBD lozenge
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) and Vectura Fertin Pharma, Inc. have launched the Luo CBD lozenge in Canada. This marks Vectura Fertin Pharma's first medical cannabis CBD product in the Canadian market. The lozenge, developed by Vectura Fertin Pharma, is manufactured by its subsidiary Cogent and distributed through Aurora's direct-to-patient e-commerce platform.
The collaboration aims to leverage Aurora's leading Canadian medical cannabis patient platform. The novel dissolvable format of the CBD lozenge offers easy dosing for patients. This launch follows the recent announcement of a commercial partnership between Cogent and Aurora, with plans to explore future medical cannabis product launches in Canada.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) e Vectura Fertin Pharma, Inc. hanno lanciato la compressa Luo CBD in Canada. Questo segna il primo prodotto di cannabis medica CBD di Vectura Fertin Pharma nel mercato canadese. La compressa, sviluppata da Vectura Fertin Pharma, è prodotta dalla sua controllata Cogent e distribuita attraverso la piattaforma e-commerce diretto al paziente di Aurora.
La collaborazione mira a sfruttare la piattaforma leader di Aurora per i pazienti di cannabis medica in Canada. Il nuovo formato dissolvibile della compressa di CBD offre un dosaggio facile per i pazienti. Questo lancio segue l'annuncio recente di una partnership commerciale tra Cogent e Aurora, con piani per esplorare futuri lanci di prodotti di cannabis medica in Canada.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) y Vectura Fertin Pharma, Inc. han lanzado la pastilla Luo CBD en Canadá. Esto marca el primer producto de cannabis medicinal CBD de Vectura Fertin Pharma en el mercado canadiense. La pastilla, desarrollada por Vectura Fertin Pharma, es fabricada por su subsidiaria Cogent y distribuida a través de la plataforma de comercio electrónico directo al paciente de Aurora.
La colaboración tiene como objetivo aprovechar la plataforma de pacientes de cannabis medicinal líder de Aurora en Canadá. El nuevo formato soluble de la pastilla de CBD ofrece un dosaje fácil para los pacientes. Este lanzamiento sigue al anuncio reciente de una asociación comercial entre Cogent y Aurora, con planes de explorar futuros lanzamientos de productos de cannabis medicinal en Canadá.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB)와 Vectura Fertin Pharma, Inc.가 루오 CBD 로젠지를 캐나다에서 출시했습니다. 이는 Vectura Fertin Pharma의 캐나다 시장에서의 첫 번째 의료용 대마초 CBD 제품입니다. 이 로젠지는 Vectura Fertin Pharma가 개발하였으며, 그 자회사인 Cogent에서 제조하고 Aurora의 직접 환자 전자상거래 플랫폼을 통해 유통됩니다.
이 협력은 Aurora의 선도적인 캐나다 의료용 대마초 환자 플랫폼을 활용하는 것을 목표로 합니다. CBD 로젠지의 새로운 용해형 형식은 환자에게 쉽게 복용할 수 있는 방법을 제공합니다. 이 출시 이후, Cogent와 Aurora 간의 상업적 파트너십 발표가 있었으며, 향후 캐나다에서의 의료용 대마초 제품 출시를 탐색할 계획이 있습니다.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) et Vectura Fertin Pharma, Inc. ont lancé le bonbon Luo CBD au Canada. Cela marque le premier produit de cannabis médical CBD de Vectura Fertin Pharma sur le marché canadien. Le bonbon, développé par Vectura Fertin Pharma, est fabriqué par sa filiale Cogent et distribué via la plateforme de commerce électronique directe aux patients d'Aurora.
La collaboration vise à tirer parti de la plateforme de patients en cannabis médical d'Aurora, leader au Canada. Le nouveau format dissolvable du bonbon CBD offre une posologie facile pour les patients. Ce lancement fait suite à l'annonce récente d'un partenariat commercial entre Cogent et Aurora, avec des projets d'explorer de futurs lancements de produits de cannabis médical au Canada.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) und Vectura Fertin Pharma, Inc. haben die Luo CBD-Lutschtablette in Kanada eingeführt. Dies markiert das erste medizinische Cannabis-CBD-Produkt von Vectura Fertin Pharma auf dem kanadischen Markt. Die Lutschtablette, die von Vectura Fertin Pharma entwickelt und von deren Tochtergesellschaft Cogent hergestellt wird, wird über Auroras Direktvertriebsplattform für Patienten vertrieben.
Die Zusammenarbeit zielt darauf ab, Auroras führende Plattform für Patienten im Bereich medizinisches Cannabis in Kanada zu nutzen. Das neuartige lösliche Format der CBD-Lutschtablette ermöglicht eine einfache Dosierung für Patienten. Diese Einführung folgt der jüngsten Ankündigung einer kommerziellen Partnerschaft zwischen Cogent und Aurora, mit Plänen zur Erkundung zukünftiger Produkteinführungen im Bereich medizinisches Cannabis in Kanada.
- Launch of new CBD lozenge product in Canada
- Expansion of product portfolio in the medical cannabis market
- Potential for future product launches through the collaboration
- Access to real-world patient data for product validation and improvement
- None.
Insights
The launch of Vectura Fertin Pharma's Luo CBD lozenge in Canada marks a significant advancement in medical cannabis delivery systems. This novel dissolvable format offers potential benefits in terms of ease of dosing and improved bioavailability. The lozenge's development under stringent safety and quality standards suggests a move towards more pharmaceutical-grade cannabis products.
The collaboration between Aurora and Vectura Fertin Pharma could lead to valuable real-world data collection, which is important for validating the efficacy of medical cannabis products. This data-driven approach may pave the way for more targeted and effective cannabis-based treatments in the future. However, it's important to note that while promising, the clinical benefits of this specific CBD lozenge formulation remain to be fully established through rigorous studies.
This partnership between Aurora and Vectura Fertin Pharma represents a strategic move in the evolving medical cannabis market. By leveraging Aurora's leading patient platform in Canada, Vectura Fertin Pharma gains valuable access to a large user base for product validation and real-world data collection. This could accelerate their product development cycle and market penetration.
For Aurora, this collaboration enhances their product portfolio with innovative delivery systems, potentially strengthening their market position in the competitive medical cannabis sector. The focus on novel formats and ease of use could attract new patient segments and increase patient adherence. However, the success of this venture will depend on patient acceptance, regulatory landscape evolution and the ability to differentiate from other CBD products in an increasingly crowded market.
Launch represents Vectura Fertin Pharma's first medical cannabis CBD lozenge to be
introduced in
Launch follows announcement of commercial collaboration between Cogent International, a
Vectura Fertin Pharma subsidiary, and Aurora to leverage Aurora's Canadian medical cannabis
patient platform
Collaboration will explore the potential to launch Vectura Fertin Pharma's future medical
cannabis portfolio in
The high-quality CBD lozenge was developed by Vectura Fertin Pharma and adheres to stringent safety, quality and regulatory standards to address unmet medical and health needs. It is the first of Vectura Fertin Pharma's medical cannabis products to launch in
Miguel Martin, CEO for Aurora said: "As the leading provider of medical cannabis in
Michael Kunst, CEO for Vectura Fertin Pharma, said: "The launch of our newly developed Luo CBD lozenge on Aurora's medical cannabis patient platform closely follows the announcement of our joint commercial collaboration in August this year, and is testament to our pioneering approach to science-backed innovation to address unmet medical and health needs. Aurora has the largest patient platform in
Through Aurora's leading patient platform, Cogent will gain access to patient feedback on the CBD lozenge, which will be used to validate the product proposition and to build real-world patient data to inform future products. The two companies will explore opportunities regarding the potential commercialisation of other Vectura Fertin Pharma medical cannabis products in
About Aurora Cannabis
Aurora is opening the world to cannabis, serving both the medical and consumer markets across
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
About Vectura Fertin Pharma
At Vectura Fertin Pharma, we are developing and commercializing a proprietary pipeline of differentiated products and brands in wellness and healthcare that address unmet patient and consumer needs. We have unique R&D capabilities in inhaled and oral technology, which we are applying across four key areas: Cannabinoids, Inhaled Therapeutics, Nicotine Replacement Therapy and Consumer Health. Underpinned by scientific rigor, and patient and consumer insights, we are passionate about finding new and better ways to help people take care of their health and wellbeing. Vectura Fertin Pharma was formed in March 2022 following the acquisition of Fertin Pharma, Vectura Group PLC and OtiTopic by Philip Morris International. For more information, visit www.vecturafertinpharma.com or LinkedIn.
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the launch of Vectura Fertin Pharma's Luo CBD lozenge on the Company's Canadian medical e-commerce platform, the Company's commitment to bringing innovative solutions to patients, and the potential to launch Vectura Fertin Pharma's future medical cannabis portfolio in
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and nongovernment consumer sales channels, management's estimates of consumer demand in
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-and-vectura-fertin-pharma-inc-announce-launch-of-novel-luo-cbd-lozenge-302241433.html
SOURCE Aurora Cannabis Inc.
FAQ
What is the new product launched by Aurora Cannabis (ACB) and Vectura Fertin Pharma?
How will the Luo CBD lozenge be distributed by Aurora Cannabis (ACB)?
What is the significance of this launch for Vectura Fertin Pharma?
How will Aurora Cannabis (ACB) and Vectura Fertin Pharma benefit from this collaboration?
